Kelly Neil J, Chan Stephen Y
Center for Pulmonary Vascular Biology and Medicine and Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute; Division of Cardiology; Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
Rev Cardiovasc Med. 2022;23(11). doi: 10.31083/j.rcm2311378. Epub 2022 Nov 9.
Pulmonary arterial hypertension (PAH) is an enigmatic and deadly vascular disease with no known cure. Recent years have seen rapid advances in our understanding of the molecular underpinnings of PAH, with an expanding knowledge of the molecular, cellular, and systems-level drivers of disease that are being translated into novel therapeutic modalities. Simultaneous advances in clinical technology have led to a growing list of tools with potential application to diagnosis and phenotyping. Guided by fundamental biology, these developments hold the potential to usher in a new era of personalized medicine in PAH with broad implications for patient management and great promise for improved outcomes.
肺动脉高压（PAH）是一种神秘且致命的血管疾病，尚无已知的治愈方法。近年来，我们对PAH分子基础的理解取得了迅速进展，对疾病的分子、细胞和系统水平驱动因素的认识不断扩展，这些认识正转化为新的治疗方式。同时，临床技术的进步导致了越来越多有潜在诊断和表型分析应用价值的工具。在基础生物学的指导下，这些进展有可能开创PAH个性化医疗的新时代，对患者管理具有广泛影响，并有望改善治疗结果。
